Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2018 Apr 6;498(3):495-501. doi: 10.1016/j.bbrc.2018.03.007. Epub 2018 Mar 15.

MFAP5 promotes tumor progression and bone metastasis by regulating ERK/MMP signaling pathways in breast cancer.

Author information

1
Department of Musculoskeletal Tumor, Shanghai Cancer Center, Fudan University, Shanghai, China.
2
Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
3
Department of Musculoskeletal Tumor, Shanghai Cancer Center, Fudan University, Shanghai, China; Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
4
Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China. Electronic address: jianruxiao83@163.com.
5
Department of Musculoskeletal Tumor, Shanghai Cancer Center, Fudan University, Shanghai, China; Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China. Electronic address: spinetumor@163.com.

Abstract

Breast cancer accounts for about 30% of all cancers in women, while approximately 70% breast cancer patients developed bone metastases throughout the course of their disease, highlighting the importance of exploring new therapeutic targets. Microfibrillar-associated protein 5 (MFAP5) is a component of extracellular elastic microfibril which has been confirmed to function in tissue development and cancer progression. But the role of MFAP5 in breast cancer remains unclear. The present study demonstrated that MFAP5 was up-regulated in breast cancers compared with that in normal breast tissues, and further increased in breast cancer bone metastasis. Functionally, MFAP5 overexpression accelerated breast cancer cell proliferation and migration, while an opposite effect was observed when MFAP5 was knocked down. In addition, up-regulation of MFAP5 increased the expression of MMP2 and MMP9 and activated the ERK signaling pathway. Conversely, inhibition of MFAP5 suppressed the expression of MMP2, MMP9, p-FAK, p-Erk1/2 and p-cJun. These findings may provide a better understanding about the mechanism of breast cancer and suggest that MFAP5 may be a potential prognostic biomarker and therapeutic target for breast cancer, especially for bone metastasis of breast cancer.

KEYWORDS:

Bone metastasis; Breast cancer; Cell migration; Cell proliferation; ERK/MMP signaling; MFAP5

PMID:
29526753
DOI:
10.1016/j.bbrc.2018.03.007

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center